NRT6003 Injection

DRUG2 trials

Sponsors

Chengdu New Radiomedicine Technology Co. LTD.

Conditions

Unresectable Hepatocellular Carcinoma

Phase 1

Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma

CompletedNCT06310590

Chengdu New Radiomedicine Technology Co. LTD.Unresectable Hepatocellular Carcinoma

Start: 2023-08-08End: 2025-06-10Updated: 2026-02-03

Phase 3

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

RecruitingNCT06900543

Chengdu New Radiomedicine Technology Co. LTD.Unresectable Hepatocellular Carcinoma

Start: 2025-04-15End: 2027-12-31Target: 108Updated: 2025-05-20